JNJ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Johnson & Johnson (JNJ) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and potential growth catalysts outweigh the minor technical and insider selling concerns. The stock's stability and defensive nature make it suitable for long-term holding.
The technical indicators are neutral with no strong buy or sell signals. The MACD is below zero but contracting negatively, RSI is neutral at 52.827, and moving averages are converging. The stock is trading near its pivot level of 238.706, with resistance at 243.807 and support at 233.605.
Strong financial performance in Q4 2025 with revenue up 9.08% YoY and net income up 49.11% YoY.
Positive analyst sentiment with multiple price target increases, including HSBC and UBS raising targets to $
Strategic portfolio adjustments, including exiting biotech companies and retaining stakes in potential acquisition targets.
Collaboration with Nanobiotix on NBTXR3, with positive Phase 1 trial results.
Defensive nature of the stock in uncertain macroeconomic conditions.
Insider selling has increased significantly by 159.20% over the last month.
MACD and RSI indicators show no clear bullish momentum.
Gross margin dropped slightly by -0.95% YoY in Q4 2025.
In Q4 2025, Johnson & Johnson reported strong financial results: Revenue increased by 9.08% YoY to $24.56 billion, net income surged by 49.11% YoY to $5.12 billion, and EPS rose by 48.23% YoY to $2.09. However, gross margin slightly declined to 67.79%, down -0.95% YoY.
Analysts are broadly positive on JNJ. Recent upgrades include HSBC and UBS raising price targets to $280 with Buy ratings, citing strong growth in pharma and medtech segments. Barclays and Citi also increased their targets, highlighting robust U.S. pharma growth and healthy sector fundamentals.
